""Don’t be ridiculous. Large rebates are normal on high-volume contracts for hospital drugs.""
Well imo,,,this specific instance is really about a "black box label, tainted product" vs "a new FDA approved untainted product",,,,it wont be very long finding out whether KG successfully signs any new long term contracts (vs the BAYER/ZGEN sales force promoting rThrombin)
KG should certainly PR their wins,,,they have too much $$$ at stake.
This should be about scientific progress,,, not about product purchase cost savings.
Market Data 
Markets 
AI
